bioMérieux has created a new fungal susceptibility card for susceptibility testing of Candida species and Cryptococcus neoformans. The VITEK 2 ASTYS07 card includes a sixth antifungal agent, micafungin, providing a valuable enhancement to antifungal susceptibility testing.
Yeast infections have become a major cause of morbidity and mortality in at-risk patient populations. Early diagnosis and prompt treatment are key to achieving successful outcomes in these infections, and bioMérieux’s VITEK 2 instrument offers automated, standardised and rapid yeast susceptibility
testing.
The VITEK 2 AST-YS07 fungal susceptibility card, which replaces VITEK 2 AST-YS06, complements the current antifungals – amphotericin B, caspofungin, fluconazole, flucytosine and voriconazole – with micafungin, an echinocandin active against Candida species, extending the capabilities of the
VITEK 2 and helping to ensure that the correct treatment is initiated swiftly.
www.biomerieux.com
